Integrated disease management approaches are increasingly promoted as a means of improving the effectiveness and efficiency of healthcare for chronic diseases such as HIV/AIDS. Novel anti‐HIV broadly neutralizing monoclonal antibodies (bnAbs)  hold promise in the prevention and treatment of HIV‐1 infection. bnAbs play a protective role by preventing the virus’s entry by interfering with its binding with the receptor present on the host cell. These antibodies are called “broadly neutralizing” as they act against several of the sub-populations of HIV.

To develop an effective bnAbs-based preventive and therapeutic solution for HIV, it is also critical to assess people living with HIV (PLHIV) categorized into different risk groups. The HIV lab at THSTI has embarked on a project to assess the potential of lead bnAbs for prevention and therapy in the Indian subtype C viruses.

THSTI will be partnering with the National Institute for Research in Reproductive Health (ICMR- NIRRH), Mumbai; YR Gaitonde Center for AIDS Research & Education (YRG CARE), Chennai; T N Medical College & B Y L Nair Hospital, Mumbai; Calcutta School of Tropical Medicine, Kolkata; AIDS Vaccine Research & Development, Duke University Medical Center, Durham, North Carolina, USA and the Neutralizing Antibody Center at the Scripps Research Institute, La Jolla, California, USA. The project will be led by Dr. Jayanta Bhattacharya.

Here's the announcement on Wellcome/DBT India Alliance’s website: https://www.indiaalliance.org/news/388